Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2JF0S
|
|||
| Drug Name |
JNJ-40411813
|
|||
| Synonyms |
JNJ-40411813; 1127498-03-6; ADX-71149; JNJ40411813; JNJ 40411813; 2(1H)-Pyridinone, 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-; 1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)pyridin-2-one; CHEMBL3337527; 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone; 1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)pyridin-2(1H)-one; 612BYT76F3; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-one; 1-butyl-3-chloranyl-4-(4-phenylpiperidin-1-yl)pyridin-2-one; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-(1,4')bipyridinyl-2'-one; HYOGJHCDLQSAHX-UHFFFAOYSA-N; ADX71149; HZR; ADX 71149; UNII-612BYT76F3; GTPL8946; SCHEMBL1035416; DTXSID601032323; BCP23709; CVB49803; EX-A2902; BDBM50051408; CS-3357; DB12059; SB16990; ADX-71149ADX-71149; NCGC00485897-01; AC-35478; HY-15748; MS-25297; FT-0752754; F85059; JNJ-40411813; ADX-71149; A894527; Q27895859; 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-2(1H)-Pyridinone; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1 'H-[1,4']bipyridinyl-2'-one; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4]bipyridinyl-2'-one; JNJ-40411813; JNJ 40411813; ADX71149; ADX 71149; ADX-71149
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Phase 2 | [1] | |
| Company |
JOHNSON & JOHNSON
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H25ClN2O
|
|||
| Canonical SMILES |
CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
|
|||
| InChI |
InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
|
|||
| InChIKey |
HYOGJHCDLQSAHX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04836559) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects With Focal Onset Seizures With Suboptimal Response to Levetiracetam or Brivaracetam. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.